+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gemifloxacin Market - Global Forecast 2025-2030- Product Image
Gemifloxacin Market - Global Forecast 2025-2030- Product Image
Sale

Gemifloxacin Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5977928
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Gemifloxacin market is evolving rapidly as global healthcare systems confront multidrug-resistant infections and adopt more innovative, patient-driven treatment models. Senior executives need to understand shifting clinical demand, regulatory nuances, and strategic competitive movements that influence near- and long-term market outlook.

Market Snapshot: Gemifloxacin Market Size and Growth

The Gemifloxacin market grew from USD 741.01 million in 2024 to USD 777.74 million in 2025. It is projected to maintain growth at a CAGR of 4.86%, reaching USD 985.58 million by 2030. This demonstrates sustained demand among healthcare providers seeking effective agents against complex respiratory tract infections and evolving treatment paradigms.

Scope & Segmentation

This report delivers an in-depth analysis of the Gemifloxacin market across clinical, distribution, and geographic parameters. It identifies emerging dynamics that matter for decision-makers evaluating investment and expansion opportunities.

  • Indications: Chronic Bronchitis, Community Acquired Pneumonia
  • Distribution Channels: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • End Users: Ambulatory Surgical Centers, Clinics, Hospitals
  • Regional Coverage: Americas (United States—with details for California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio—Canada, Mexico, Brazil, Argentina) Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland) Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Featured Companies: Mylan N.V., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Cipla Ltd, Lupin Ltd, Dr. Reddy’s Laboratories Ltd, Aurobindo Pharma Ltd, Sun Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd, Cadila Healthcare Ltd

Key Takeaways for Senior Decision-Makers

  • The rise in multidrug-resistant pathogens is increasing reliance on next-generation fluoroquinolones, with Gemifloxacin positioned as a strategic option due to its antibacterial profile and efficacy against challenging respiratory tract infections.
  • Digital health adoption—including telemedicine and advanced prescribing platforms—has streamlined Gemifloxacin access and is reshaping prescription channel dynamics, especially where precision medicine is prioritized.
  • Payer-driven focus on value-based care and cost containment is accelerating the adoption of therapies that can demonstrate improved patient outcomes and reductions in hospital readmissions, aligning with Gemifloxacin’s profile.
  • Collaborations between manufacturers, pharmacy networks, and diagnostic providers are supporting wider market access, integration of real-time resistance data, and more efficient supply chain operations.
  • Regional differences in regulatory oversight, healthcare investment, and epidemiology continue to impact uptake trajectories, with Asia-Pacific emerging as a key frontier for future demand growth due to demographic trends and increasing antibiotic stewardship.
  • Diversification of sourcing strategies and manufacturing partnerships has fostered agility in response to macroeconomic shifts and market access barriers.

Tariff Impact: Navigating the 2025 US Trade Policy Shift

The 2025 introduction of new US tariffs created significant cost pressures in pharmaceutical supply chains, particularly for Gemifloxacin, by elevating active ingredient sourcing expenses. Market players responded by accelerating supplier diversification, optimizing logistics, and recalibrating pricing structures. Strategic procurement from emerging markets and domestic sources reinforced continuity and competitive pricing, while contracting arrangements with payers tied access to measurable health outcomes.

Methodology & Data Sources

The analysis leverages a multi-pronged approach. Primary data was gathered through structured interviews with infectious disease experts, pharmacy directors, and supply chain managers. Secondary research included a review of peer-reviewed literature, regulatory filings, and open-access market databases. Findings were cross-validated using advanced statistical methods and triangulated to ensure data rigor and relevance.

Why This Report Matters

  • Provides executives with actionable segmentation and regional insights to inform resource allocation and go-to-market planning.
  • Equips strategic planners with a detailed understanding of supply chain vulnerabilities and mitigation strategies amid evolving trade policies.
  • Highlights market drivers behind Gemifloxacin adoption, supporting better investment, licensing, and alliance decisions.

Conclusion

Understanding shifts in antibiotic resistance, policy, and distribution can yield significant commercial and clinical advantages. By leveraging these insights and implementing recommended strategies, industry leaders can drive competitive differentiation and contribute meaningfully to the evolving antibiotic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Evaluation of gemifloxacin patent expiration impact on generic market entry strategies
5.2. Surge in multidrug resistant pathogens driving demand for advanced fluoroquinolone therapies
5.3. Regional regulatory shifts in Asia Pacific influencing gemifloxacin approval timelines and market access
5.4. Rising investment in novel oral antibiotic formulations to enhance gemifloxacin bioavailability and adherence
5.5. Integration of digital antibiotic stewardship programs to optimize gemifloxacin prescription and usage patterns
5.6. Competitive landscape transformation with biosimilar and generic entrants challenging branded gemifloxacin sales volumes
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gemifloxacin Market, by Indication
8.1. Introduction
8.2. Chronic Bronchitis
8.3. Community Acquired Pneumonia
9. Gemifloxacin Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Gemifloxacin Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Clinics
10.4. Hospitals
11. Americas Gemifloxacin Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Gemifloxacin Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Gemifloxacin Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Mylan N.V.
14.3.2. Teva Pharmaceutical Industries Ltd
14.3.3. Sandoz International GmbH
14.3.4. Cipla Ltd
14.3.5. Lupin Ltd
14.3.6. Dr. Reddy’s Laboratories Ltd
14.3.7. Aurobindo Pharma Ltd
14.3.8. Sun Pharmaceutical Industries Ltd
14.3.9. Torrent Pharmaceuticals Ltd
14.3.10. Cadila Healthcare Ltd
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. GEMIFLOXACIN MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GEMIFLOXACIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GEMIFLOXACIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GEMIFLOXACIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 12. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 14. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GEMIFLOXACIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 20. GEMIFLOXACIN MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 21. GEMIFLOXACIN MARKET: RESEARCHAI
FIGURE 22. GEMIFLOXACIN MARKET: RESEARCHSTATISTICS
FIGURE 23. GEMIFLOXACIN MARKET: RESEARCHCONTACTS
FIGURE 24. GEMIFLOXACIN MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GEMIFLOXACIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GEMIFLOXACIN MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GEMIFLOXACIN MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GEMIFLOXACIN MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GEMIFLOXACIN MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GEMIFLOXACIN MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GEMIFLOXACIN MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GEMIFLOXACIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GEMIFLOXACIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GEMIFLOXACIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GEMIFLOXACIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GEMIFLOXACIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GEMIFLOXACIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GEMIFLOXACIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GEMIFLOXACIN MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GEMIFLOXACIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GEMIFLOXACIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. AMERICAS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 32. AMERICAS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 33. AMERICAS GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 34. AMERICAS GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 35. AMERICAS GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 36. AMERICAS GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 37. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 38. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 39. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 40. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 41. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 42. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 43. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 44. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 45. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 46. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 47. CANADA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 48. CANADA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 49. CANADA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. CANADA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. CANADA GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 52. CANADA GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 53. MEXICO GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 54. MEXICO GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 55. MEXICO GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. MEXICO GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. MEXICO GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. MEXICO GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. BRAZIL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 60. BRAZIL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 61. BRAZIL GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. BRAZIL GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. BRAZIL GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 64. BRAZIL GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 65. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 66. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 67. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 68. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 69. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 79. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 80. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. GERMANY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. GERMANY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. GERMANY GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. GERMANY GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. GERMANY GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. GERMANY GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. FRANCE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. FRANCE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. FRANCE GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. FRANCE GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. FRANCE GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. FRANCE GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. RUSSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. RUSSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. RUSSIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. RUSSIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. RUSSIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. RUSSIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. ITALY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 104. ITALY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 105. ITALY GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. ITALY GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. ITALY GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. ITALY GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. SPAIN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. SPAIN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. SPAIN GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. SPAIN GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. SPAIN GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. SPAIN GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 116. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 117. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 128. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. DENMARK GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. DENMARK GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. DENMARK GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. DENMARK GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. DENMARK GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. DENMARK GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. QATAR GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 146. QATAR GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 147. QATAR GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. QATAR GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. QATAR GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. QATAR GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. FINLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 152. FINLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 153. FINLAND GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. FINLAND GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. FINLAND GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. FINLAND GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. SWEDEN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 158. SWEDEN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 159. SWEDEN GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. SWEDEN GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. SWEDEN GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. SWEDEN GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. NIGERIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. NIGERIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. NIGERIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. NIGERIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. NIGERIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. NIGERIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. EGYPT GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 170. EGYPT GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 171. EGYPT GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. EGYPT GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. EGYPT GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. EGYPT GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. TURKEY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 176. TURKEY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 177. TURKEY GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. TURKEY GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. TURKEY GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. TURKEY GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. ISRAEL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. ISRAEL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. ISRAEL GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. ISRAEL GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. ISRAEL GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. ISRAEL GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. NORWAY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 188. NORWAY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 189. NORWAY GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. NORWAY GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. NORWAY GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. NORWAY GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. POLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 194. POLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 195. POLAND GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. POLAND GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. POLAND GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. POLAND GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 212. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 213. CHINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 214. CHINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 215. CHINA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. CHINA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. CHINA GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. CHINA GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. INDIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. INDIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. INDIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. INDIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. INDIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. INDIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. JAPAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 226. JAPAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 227. JAPAN GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. JAPAN GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. JAPAN GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. JAPAN GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 238. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 239. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. INDONESIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. INDONESIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. INDONESIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. INDONESIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. INDONESIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. INDONESIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. THAILAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. THAILAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. THAILAND GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. THAILAND GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. THAILAND GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. THAILAND GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. VIETNAM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 274. VIETNAM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 275. VIETNAM GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. VIETNAM GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. VIETNAM GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. VIETNAM GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. TAIWAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 280. TAIWAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 281. TAIWAN GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. TAIWAN GEMIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. TAIWAN GEMIFLOXACIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. TAIWAN GEMIFLOXACIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. GEMIFLOXACIN MARKET SHARE, BY KEY PLAYER, 2024
TABLE 286. GEMIFLOXACIN MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Gemifloxacin market report include:
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Cipla Ltd
  • Lupin Ltd
  • Dr. Reddy’s Laboratories Ltd
  • Aurobindo Pharma Ltd
  • Sun Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd
  • Cadila Healthcare Ltd

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 777.74 Million
Forecasted Market Value ( USD ) by 2030 $ 985.58 Million
Compound Annual Growth Rate4.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gemifloxacin (CAS 175463-14-6) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Gemifloxacin (CAS 175463-14-6) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Eprazinone Market - Global Forecast 2025-2030 - Product Image

Eprazinone Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Acetylcysteine Market - Global Forecast 2025-2030 - Product Image

Acetylcysteine Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
COPD and Asthma Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Anti-Inflammatory, Bronchodilators), Device/Product (Inhalers), Technology/Software, Indication, Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

COPD and Asthma Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Anti-Inflammatory, Bronchodilators), Device/Product (Inhalers), Technology/Software, Indication, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Zinplava Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Zinplava Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From

About the Gemifloxacin Market

Gemifloxacin is an antibiotic used to treat a variety of bacterial infections. It belongs to a class of antibiotics known as fluoroquinolones, which work by inhibiting the growth of bacteria. Gemifloxacin is used to treat respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other bacterial infections. It is available in tablet and oral suspension form. Gemifloxacin is a relatively new antibiotic, and is not widely used. It is generally reserved for cases where other antibiotics have failed or are not suitable. It is generally well tolerated, with few side effects. The market for gemifloxacin is relatively small, and is dominated by a few major pharmaceutical companies. These include Merck, Pfizer, and GlaxoSmithKline. Other companies, such as Teva Pharmaceuticals and Mylan, also produce generic versions of the drug. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.